Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Abstract Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jörg T Regula, Peter Lundh von Leithner, Richard Foxton, Veluchamy A Barathi, Chui Ming Gemmy Cheung, Sai Bo Bo Tun, Yeo Sia Wey, Daiju Iwata, Miroslav Dostalek, Jörg Moelleken, Kay G Stubenrauch, Everson Nogoceke, Gabriella Widmer, Pamela Strassburger, Michael J Koss, Christian Klein, David T Shima, Guido Hartmann
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer Nature 2016-10-01
Col·lecció:	EMBO Molecular Medicine
Matèries:	age‐related macular degeneration angiogenesis angiopoietin‐2 Fc receptor vascular endothelial growth factor
Accés en línia:	https://doi.org/10.15252/emmm.201505889
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!